| ²é¿´: 628 | »Ø¸´: 9 | |||
[½»Á÷]
Science£º×¢ÉäÇ¿Á¦¿¹ÌåÒÖÖÆÑªÒºÖÐHIV²¡¶¾
|
|||
|
12ÔÂ23ÈÕ£¬À´×ÔÃÀ¹úNIHµÄ¿ÆÑ§¼ÒÃÇÔÚ¹ú¼ÊѧÊõÆÚ¿¯ÉÏ·¢±íÁËÒ»Ïî×îÐÂÑо¿½øÕ¹£¬ËûÃDZ¨¸æ³Æ×¢ÉäÒ»ÖÖ½Ð×öVRC01µÄǿЧ¿¹Ìå¾ÍÄܹ»ÒÖÖÆÎ´½ÓÊÜ¿¹Äæ×ªÂ¼²¡¶¾ÖÎÁƵÄHIVЯ´øÕßѪҺÖеÄHIV²¡¶¾Ë®Æ½¡£Ñо¿ÈËÔ±»¹·¢ÏÖͨ¹ý¾²Âö×¢Éä»òƤÏÂ×¢É䷽ʽ½«VRC01¿¹Ìå×¢È벡¶¾Ð¯´øÕßÌåÄÚ¾ßÓзdz£ºÃµÄ°²È«ÐÔºÍÄÍÊÜÐÔ£¬²¢ÇÒ×¢ÈëµÄ¿¹ÌåÄܹ»ÔÚ²¡ÈËѪҺÖб£³Ö½Ï³¤Ê±¼ä¡£ Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection http://stm.sciencemag.org/content/7/319/319ra206 Passive aggression for HIV Antibodies that neutralize HIV could add to the therapeutic arsenal to prevent and treat disease. Lynch et al. have now tested one such antibody¡ªVRC01¡ªin HIV-infected individuals. Although little difference was observed in viral reservoir in individuals on antiretroviral therapy, plasma viremia was reduced in untreated subjects with a single infusion of VRC01, preferentially suppressing neutralization-sensitive strains. Passive immunization with neutralizing antibodies could therefore aid in viral suppression in HIV-infected individuals. Abstract Passive immunization with HIV-1¨Cneutralizing monoclonal antibodies (mAbs) is being considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be used to suppress active virus replication, maintain suppression induced by antiretroviral therapy (ART), and/or decrease the size of the persistent virus reservoir. We assessed the impact of VRC01, a potent human mAb targeting the HIV-1 CD4 binding site, on ART-treated and untreated HIV-1¨Cinfected subjects. Among six ART-treated individuals with undetectable plasma viremia, two infusions of VRC01 did not reduce the peripheral blood cell¨Cassociated virus reservoir measured 4 weeks after the second infusion. In contrast, six of eight ART-untreated, viremic subjects infused with a single dose of VRC01 experienced a 1.1 to 1.8 log10 reduction in plasma viremia. The two subjects with minimal responses to VRC01 were found to have predominantly VRC01-resistant virus before treatment. Notably, two subjects with plasma virus load <1000 copies/ml demonstrated virus suppression to undetectable levels for over 20 days until VRC01 levels declined. Among the remaining four subjects with baseline virus loads between 3000 and 30,000 copies, viremia was only partially suppressed by mAb infusion, and we observed strong selection pressure for the outgrowth of less neutralization-sensitive viruses. In summary, a single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains. These data demonstrate the virological effect of this neutralizing antibody and highlight the need for combination strategies to maintain virus suppression. |
» ²ÂÄãϲ»¶
ÇóÖú¡¶ÉúÎïÀûÓöȺÍÉúÎïµÈЧÐÔÑо¿Ö¸µ¼ÔÔò¡·£¨ÊÔ ÐУ©£¬2002
ÒѾÓÐ0È˻ظ´
¸÷λ´óÀУ¬H¿ÚÃæÉÏʲôʱºò»áÆÀ£¿£¿£¿
ÒѾÓÐ30È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ300È˻ظ´
ÎÄÏ×ÇóÖú
ÒѾÓÐ0È˻ظ´
2026Äêɽ¶«´óѧº£ÑóѧԺÉúÎïÓëÒ½Ò©²©Ê¿ÕÐÉú-Àîϼ¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
²©Ê¿Ñо¿ÉúÕÐÉú
ÒѾÓÐ0È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
¿¼Ñе÷¼Á£º¹ú¼Òµ°°×ÖÊ¿ÆÑ§ÖÐÐÄ£¨¹ú¼ÒÖØµãʵÑéÊÒ£©ºÍ°²»ÕÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÁªÅà
ÒѾÓÐ4È˻ظ´
»ªÄÏÀí¹¤´óѧ »ù´¡Ò½Ñ§Ñ§Ë¶ºÍÁÙ´²Ò½Ñ§Ñ§Ë¶µ÷¼Á
ÒѾÓÐ11È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ʳÎïÒ²ÄܴݻٸÎÔࣺÎÒÃÇÊÇÔõÑù³Ô³ö¸Î¹¦ÄÜË¥½ßÉõÖÁ¸Î°©µÄ£¿
ÒѾÓÐ0È˻ظ´
ºÍÔªÉúÎï2015Äê»ùÒò¹¦ÄÜÑо¿·½·¨Óëʵ¼ùÅàѵ°à¿ªÊ¼±¨ÃûÀ²£¡
ÒѾÓÐ4È˻ظ´
´ÓÄÉÃ×¼¼Êõµ½ÍâÌ«¿Õ£ºÅ̵ã2014Äê¶ÈÊ®´ó¿Æ¼¼·¢Ã÷
ÒѾÓÐ1È˻ظ´
PD-1¿¹Ì壺°©Ö¢ÃâÒßÁÆ·¨µÄÑз¢¾ºÈü
ÒѾÓÐ14È˻ظ´
£¨×îÐÂÖÁ2013.10£©ÄÉÃ×¼¼ÊõÓëÉúÎïѧ½»²æÁìÓòÑо¿½øÕ¹£¨ÖÐÎļò±¨´øÓ¢ÎÄÕªÒª£©
ÒѾÓÐ343È˻ظ´
ScienceÆæÎÄ£º¼ÙÂÛÎÄ»»À´Õæ½ÓÊÕ
ÒѾÓÐ15È˻ظ´
Nature£ºÈ«ÀÀϸ°ûÅàÑø¼¼Êõ×îÐÂÇ°ÑØ
ÒѾÓÐ20È˻ظ´
×¢Éä¼ÁлᣨPDA)ÕýÔÚÐÞ¶©ÎÞ¾úÒ©Æ·µÄ¼¼Êõ±¨¸æ
ÒѾÓÐ5È˻ظ´
·ÖÎö»¯Ñ§×îÐÂÆÚ¿¯»ã×ܵÚÒ»¼¾£¨10ƪ£©
ÒѾÓÐ28È˻ظ´
ÔÚ¡¶Science¡·ÉÏ·¢±íÂÛÎÄ£¬ÄÑ£¬»¹ÊDz»ÄÑ£¿
ÒѾÓÐ16È˻ظ´
ÔÚ¡¶Science¡·ÉÏ·¢±íÂÛÎÄ
ÒѾÓÐ14È˻ظ´
Öйú¸ßУ·¢±íScienceÎÄÕÂ×îÐÂÅÅÃû
ÒѾÓÐ17È˻ظ´
¡¾×ªÌû¡¿¡¶×ÔÈ»¡ªÉñ¾¿ÆÑ§¡·£ºÕë¾Äֹʹ´æÔÚ¿ÆÑ§ÔÀí
ÒѾÓÐ8È˻ظ´
¡¾×ªÌû¡¿¡¶×ÔÈ»¡ªÉñ¾¿ÆÑ§¡·£ºÕë¾Äֹʹ´æÔÚ¿ÆÑ§ÔÀí
ÒѾÓÐ1È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
¡¾×ø±ê´óÁ¬¡¿92Äê±¾¿ÆÄÐÉú£¬Ñ°ÃÙÒöԵŮÉú
+5/401
Õã½Ê¦·¶´óѧÊýÀíҽѧԺÕÐÆ¸×¨ÈνÌʦ
+5/240
ÑÓ°²´óѧ»¯Ñ§Ó뻯¹¤Ñ§Ôº½ÓÊÕ»¯Ñ§×¨Òµµ÷¼ÁÉú£¬4ÔÂ12ÈÕÏÂÎ縴ÊÔ£¨¹¤¿Æ¡¢Àíѧ¾ù¿Éµ÷¼Á£©
+1/188
É¿ƴ󻷾³Ñ§ÔºÕÐÊÕ0857ºÍ0830µ÷¼Á¿¼Éú¡¾¿É¿çÃÅÀ࣬×îºó2Á½Ð¡Ê±¡¿
+1/186
¡ï¡ï¾«Æ·¡ï¡ï0860ÉúÎïÓëÒ½Ò©»¹Óе÷¼ÁÖ¸±ê£¬×îºóµÄ»ú»á£¬¼ñ©Éϰ¶
+1/131
ºþ±±ÎÄÀíѧԺ£¬²ÄÁÏ£¬»¯Ñ§£¬»·¾³£¬»úе£¬µç×Ó£¬¹¤³ÌµÈרҵ¾ù¿É±¨Ãûµ÷¼Á£¡
+3/104
µ±ÐÂÄÜÔ´²»ÔÙÊÇÒ»¸öÑ¡ÔñÌâ
+1/92
Õ㽿Ƽ¼´óѧ»·¾³Óë×ÊԴѧԺ2026Äê˶ʿÑо¿ÉúÕÐÉú
+1/88
´óÍåÇø´óѧÀîºì¸ýÓëÖйú¿ÆÑ§¼¼Êõ´óѧÍõÁø½ÌÊÚÁªºÏÕÐÊÕ²©Ê¿ºó
+1/85
ºÓÄÏʦ·¶´óѧ²ÄÁÏѧԺÕÐÉúµ÷¼ÁÉú
+2/40
ÖÐÒ½Ò©¹ã¶«Ê¡ÊµÑéÉúÎï³ÉÏñÍŶӵ÷¼ÁÐÅÏ¢
+1/38
Ò»±¾ÔºÐ££¬»¯Ñ§¡¢»·¾³¹¤³Ì£¬Éϳµ¾Í×ß
+1/21
±±¾©Àí¹¤´óѧ£¨Ö麣£©ÕÐÊÕÈ˹¤ÖÇÄÜ·½Ïò26¼¶²©Ê¿
+1/21
AIRS΢ÄÉ»úÆ÷ÈËÖÐÐijÏÕÐÑо¿ÐÍ˶ʿÉú£¨Mphil£©¡¢È«Ö°¿ÆÑÐÖúÀí£¨RA£©¡¢ÊµÏ°Éú£¨Intern£
+1/14
ÉϺ£½»Í¨´óѧ²ÄÁϳÉÐΣ¨ËÜÐÔ¼Ó¹¤£©³£ÄêÕÐÆ¸Ë¶Ê¿Ñо¿Éú¡¢²©Ê¿Ñо¿ÉúºÍ²©Ê¿ºó
+1/10
Ê¡ÖØµãʵÑéÊÒÕÐÊÕ07רҵµ÷¼ÁÉú£¬º£ÑóÉúÎïרҵÃû¶î³ä×ã
+1/9
»ªÄÏʦ·¶´óѧ»·¾³Ñ§Ôº´ó·Ö×ÓÌåϵ¶à³ß¶ÈÄ£ÄâÓëʵÑéÑо¿ÍŶÓÕÐÊÕ2026Ä꿼Ñе÷¼ÁÉú1Ãû
+1/9
ÕҺù¤×÷À´ÎÒÕâ-¹ã¶«Î¨Ò»Ê¯»¯ÔºÐ£¡ª¡ª×ÊÔ´Óë»·¾³×¨Ë¶ÕÐÉú
+1/4
Advanced Synthesis & Catalysis ¾ö¶¨ÊÇ·ñËÍÉóÒ»°ã¶à¾Ã£¿
+1/3
Î÷°²¹¤³Ì´óѧ»·¾³Ó뻯ѧ¹¤³ÌѧԺ2026Äê˶ʿÑо¿Éúµ÷¼ÁÕÐÉú
+1/1
9Â¥2016-01-10 22:44:07
10Â¥2016-01-15 11:20:45
¼òµ¥»Ø¸´
jiantu2Â¥
2015-12-29 10:31
»Ø¸´
linglingchen(½ð±Ò+1): лл²ÎÓë
liangbk3Â¥
2015-12-29 11:05
»Ø¸´
linglingchen(½ð±Ò+1): лл²ÎÓë

bit_14Â¥
2015-12-29 11:30
»Ø¸´
linglingchen(½ð±Ò+1): лл²ÎÓë
tan9145Â¥
2015-12-29 12:10
»Ø¸´
linglingchen(½ð±Ò+1): лл²ÎÓë

tan9146Â¥
2015-12-29 12:13
»Ø¸´

psylhh7Â¥
2015-12-29 12:14
»Ø¸´
linglingchen(½ð±Ò+1): лл²ÎÓë

zy0614208978Â¥
2015-12-30 09:12
»Ø¸´















»Ø¸´´ËÂ¥